Dopamine Dysregulation Syndrome

Parkinson's Disease: Non-Motor and Non-Dopaminergic Features

Volumn , Issue , 2011, Pages 202-214

  O'Sullivan, Sean S ^a   Lees, Andrew J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Addiction; Compulsive behaviors; Dopamine dysregulation syndrome; Impulse control disorders; Parkinson's disease; Punding

Indexed keywords

EID: 84855933909     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444397970.ch19     Document Type: Chapter

References (166)

1. Evans AH, Lees AJ. Dopamine dysregulation syndrome in Parkinson's disease. Curr Opin Neurol 2004;17(4):393-8.
2. Lawrence AD, Evans AH, Lees AJ. Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry? Lancet Neurol 2003;2(10):595-604.
3. Evans AH, Katzenschlager R, Paviour D, et al. Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. Mov Disord 2004;19(4):397-405.
4. O'Brien CP, DiGiacomo JN, Fahn S, Schwarz GA. Mental effects of high-dosage levodopa. Arch Gen Psychiatry 1971;24(1):61-4.
5. Witjas T, Kaphan E, Azulay JP, et al. Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology 2002;59(3):408-13.
6. Hillen ME, Sage JI. Nonmotor fluctuations in patients with Parkinson's disease. Neurology 1996;47(5):1180-3.
7. Maricle RA, Valentine RJ, Carter J, Nutt JG. Mood response to levodopa infusion in early Parkinson's disease. Neurology 1998;50(6):1890-2.
8. Menza MA, Sage J, Marshall E, et al. Mood changes and "on-off" phenomena in Parkinson's disease. Mov Disord 1990;5(2):148-51.
9. Nissenbaum H, Quinn NP, Brown RG, et al. Mood swings associated with the "on-off" phenomenon in Parkinson's disease. Psychol Med 1987;17(4):899-904.
10. Bearn J, Evans A, KelleherM, et al. Recognition of a dopamine replacement therapy dependence syndrome in Parkinson's disease: a pilot study. Drug Alcohol Depend 2004;76(3):305-10.
11. Giovannoni G, O'Sullivan JD, Turner K, et al. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 2000;68(4):423-8.
12. Merims D, Galili-Mosberg R, Melamed E. Is there addiction to levodopa in patients with Parkinson's disease?. Mov Disord 2000;15(5):1014-6.
13. Spigset O, von Scheele C. Levodopa dependence and abuse in Parkinson's disease. Pharmacotherapy 1997;17(5):1027-30.
14. Pezzella FR, Colosimo C, Vanacore N, et al. Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson's disease. Mov Disord 2005;20(1):77-81.
15. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Association, 2000.
16. Grant JE, Levine L, Kim D, Potenza MN. Impulse control disorders in adult psychiatric inpatients. Am J Psychiatry 2005;162(11):2184-8.
17. McElroy SL, Keck PE Jr, Pope HG Jr, et al. Compulsive buying: a report of 20 cases. J Clin Psychiatry 1994;55(6):242-8.
18. Nirenberg MJ, Waters C. Compulsive eating and weight gain related to dopamine agonist use. Mov Disord 2006;21(4): 524-9.
19. Molina JA, Sainz-Artiga MJ, Fraile A, et al. Pathologic gambling in Parkinson's disease: a behavioral manifestation of pharmacologic treatment?. Mov Disord 2000;15(5):869-72.
20. Klos KJ, Bower JH, Josephs KA, et al. Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy. Parkinsonism Relat Disord 2005;11(6):381-6.
21. Voon V, Fox SH. Medication-related impulse control and repetitive behaviors in Parkinson disease. Arch Neurol 2007;64(8):1089-96.
22. Rylander G. Psychoses and the punding and choreiform syndromes in addiction to central stimulant drugs. Psychiatr Neurol Neurochir 1972;75(3):203-12.
23. Schiorring E. Psychopathology induced by "speed drugs". Pharmacol Biochem Behav 1981;14(Suppl 1):109-22.
24. Friedman JH. Punding on levodopa. Biol Psychiatry 1994;36(5):350-1.
25. Fernandez HH, Friedman JH. Punding on l-dopa. Mov Disord 1999;14(5):836-8.
26. Fasano A, Elia AE, Soleti F, et al. Punding and computer addiction in Parkinson's disease. Mov Disord 2006;21(8): 1217-8.
27. Miyasaki JM, Al Hassan K, Lang AE, Voon V. Punding prevalence in Parkinson's disease. Mov Disord 2007;22(8) 1179-81.
28. Kummer A, Maia DP, Salgado JV, et al. Dopamine dysregulation syndrome in Parkinson's disease: case report. Arq Neuropsiquiatr 2006;64(4):1019-22.
29. Shapiro MA, Chang YL, Munson SK, et al. Hypersexuality and paraphilia induced by selegiline in Parkinson's disease: report of 2 cases. Parkinsonism Relat Disord 2006;12(6): 392-5.
30. Alegret M, Junque C, Valldeoriola F, et al. Obsessive- compulsive symptoms in Parkinson's disease. J Neurol Neurosurg Psychiatry 2001;70(3):394-6.
31. Factor SA, Molho ES, Podskalny GD, Brown D. Parkinson's disease: drug-induced psychiatric states. Adv Neurol 1995;65: 115-38.
32. Voon V, Hassan K, Zurowski M, et al. Prospective prevalence of pathologic gambling and medication association in Parkinson disease. Neurology 2006;66(11):1750-2.
33. Petry NM, Stinson FS, Grant BF. Comorbidity of DSMIV pathological gambling and other psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 2005;66(5):564-74.
34. Cunningham-Williams RM, Grucza RA, Cottler LB, et al. Prevalence and predictors of pathological gambling: results from the St. Louis personality, health and lifestyle (SLPHL) study. J Psychiatr Res 2005;39(4):377-90.
35. Voon V, Hassan K, Zurowski M, et al. Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology 2006;67(7):1254-7.
36. Bathgate D, Snowden JS, Varma A, et al. Behaviour in frontotemporal dementia, Alzheimer's disease and vascular dementia. Acta Neurol Scand 2001;103(6):367-78.
37. Miyasaki JM, Al Hassan K, Lang AE, Voon V. Punding prevalence in Parkinson's disease. Mov Disord 2007;22(8):1179-81.
38. Hojsted J, Sjogren P. Addiction to opioids in chronic pain patients: a literature review. Eur J Pain 2007;11(5):490-518.
39. World Health Organization. ICD-10 Version 2007, http://www.who.int/classifications/apps/icd/icd10online/. Geneva: World Health Organization, 2007.
40. Colosimo C, Merello M, Hughes AJ, et al. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon. J Neurol Neurosurg Psychiatry 1996;60(6):634-7.
41. Cloninger CR. A systematic method for clinical description and classification of personality variants. A proposal. Arch Gen Psychiatry 1987;44(6):573-88.
42. Hosak L, Preiss M, Halir M, et al. Temperament and character inventory (TCI) personality profile in methamphetamine abusers: a controlled study. Eur Psychiatry 2004;19(4):193-5.
43. Palmgreen P, Donohew L, Lorch EP, et al. Television campaigns and adolescent marijuana use: tests of sensation seeking targeting. Am J Public Health 2001;91(2):292-6.
44. Zilberman ML, Tavares H, el-Guebaly N. Relationship between craving and personality in treatment-seeking women with substance-related disorders. BMC Psychiatry 2003;3:1.
45. Meszaros K, Lenzinger E, Hornik K, et al. The Tridimensional Personality Questionnaire as a predictor of relapse in detoxified alcohol dependents. The European Fluvoxamine in Alcoholism Study Group. Alcohol Clin Exp Res 1999;23(3): 483-6.
46. Zuckerman M. Sensation seeking and behavior disorders. Arch Gen Psychiatry 1988;45(5):502-4.
47. Leyton M, Boileau I, Benkelfat C, et al. Amphetamine-induced increases in extracellular dopamine, drug wanting, and novelty seeking: a PET/[11C]raclopride study in healthy men. Neuropsychopharmacology 2002;27(6):1027-35.
48. Todes CJ, Lees AJ. The pre-morbid personality of patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1985;48(2):97-100.
49. Menza MA, Golbe LI, Cody RA, Forman NE. Dopaminerelated personality traits in Parkinson's disease. Neurology 1993;43(3 Pt 1):505-8.
50. Poewe W, Karamat E, Kemmler GW, Gerstenbrand F. The premorbid personality of patients with Parkinson's disease: a comparative study with healthy controls and patients with essential tremor. Adv Neurol 1990;53: 339-42.
51. Fujii C, Harada S, Ohkoshi N, et al. Cross-cultural traits for personality of patients with Parkinson's disease in Japan. Am J Med Genet 2000;96(1):1-3.
52. Menza M. The personality associated with Parkinson's disease. Curr Psychiatry Rep 2000;2(5):421-6.
53. Evans AH, Lawrence AD, Potts J, et al. Relationship between impulsive sensation seeking traits, smoking, alcohol and caffeine intake, and Parkinson's disease. J Neurol Neurosurg Psychiatry 2006;77(3):317-21.
54. Ishihara L, Brayne C. What is the evidence for a premorbid parkinsonian personality: a systematic review. Mov Disord 2006;21(8):1066-72.
55. Evans AH, Lawrence AD, et al. Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease. Neurology 2005;65(10):1570-4.
56. Voon V, Thomsen T, Miyasaki JM, et al. Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. Arch Neurol 2007;64(2):212-6.
57. Lawrence AJ, Blackwell AD, Barker RA, et al. Predictors of punding in Parkinson's disease: results from a questionnaire survey. Mov Disord 2007;22(16):2339-45.
58. Chambers RA, Taylor JR, Potenza MN. Developmental neurocircuitry of motivation in adolescence: a critical period of addiction vulnerability. Am J Psychiatry 2003;160(6):1041-52.
59. Gallagher DA, O'Sullivan SS, Evans AH, et al. Pathological gambling in Parkinson's disease: risk factors and differences from dopamine dysregulation. An analysis of published case series. Mov Disord 2007;22(12):1757-63.
60. Kreek MJ, Nielsen DA, LaForge KS. Genes associated with addiction: alcoholism, opiate, and cocaine addiction. Neuromol. Med 2004;5(1):85-108.
61. Kreek MJ, Nielsen DA, Butelman ER, LaForge KS. Genetic influences on impulsivity, risk taking, stress responsivity and vulnerability to drug abuse and addiction. Nat Neurosci 2005;8(11):1450-7.
62. Blum K, Braverman ER, Holder JM, et al. Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors. J Psychoactive Drugs 2000;32(Suppl):i-iv, 1-112.
63. Blum K, Noble EP, Sheridan PJ, et al. Allelic association of human dopamine D2 receptor gene in alcoholism. JAMA 1990;263(15):2055-60.
64. Klein TA, Neumann J, Reuter M, et al. Genetically determined differences in learning from errors. Science 2007;318(5856):1642-5.
65. Cohen MX, Krohn-Grimberghe A, Elger CE, Weber B. Dopamine gene predicts the brain's response to dopaminergic drug. Eur J Neurosci 2007;26(12):3652-60.
66. Eisenberg DT, Mackillop J, Modi M, et al. Examining impulsivity as an endophenotype using a behavioral approach: a DRD2 TaqI A and DRD4 48-bp VNTR association study. Behav Brain Funct 2007;3: 2.
67. Blum K, Braverman ER, Wood RC, et al. Increased prevalence of the TaqI A1 allele of the dopamine receptor gene (DRD2) in obesity with comorbid substance use disorder: a preliminary report. Pharmacogenetics 1996;6(4):297-305.
68. Noble EP. D2 dopamine receptor gene in psychiatric and neurologic disorders and its phenotypes. Am J Med Genet B Neuropsychiatr Genet 2003;116B(1):103-25.
69. Comings DE, Ferry L, Bradshaw-Robinson S, et al. The dopamine D2 receptor (DRD2) gene: a genetic risk factor in smoking. Pharmacogenetics 1996;6(1):73-9.
70. Comings DE, Rosenthal RJ, Lesieur HR, et al. A study of the dopamine D2 receptor gene in pathological gambling. Pharmacogenetics 1996;6(3):223-34.
71. Fang YJ, Thomas GN, Xu ZL, et al. An affected pedigree member analysis of linkage between the dopamine D2 receptor gene TaqI polymorphism and obesity and hypertension. Int J Cardiol 2005;102(1):111-6.
72. Davis C, Levitan RD, Kaplan AS, et al. Reward sensitivity and the D2 dopamine receptor gene: a case-control study of binge eating disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008;32(3):620-8.
73. Strobel A, Spinath FM, Angleitner A, et al. Lack of association between polymorphisms of the dopamine D4 receptor gene and personality. Neuropsychobiology 2003;47(1):52-6.
74. Gebhardt C, Leisch F, Schussler P, et al. Non-association of dopamine D4 and D2 receptor genes with personality in healthy individuals. Psychiatr Genet 2000;10(3):131-7.
75. Tsai SJ, Hong CJ, Yu YW, Chen TJ. Association study of catechol-O-methyltransferase gene and dopamine D4 receptor gene polymorphisms and personality traits in healthy young Chinese females. Neuropsychobiology 2004;50(2): 153-6.
76. Oliveri RL, Annesi G, Zappia M, et al. The dopamine D2 receptor gene is a susceptibility locus for Parkinson's disease. Mov Disord 2000;15(1):127-31.
77. Plante-Bordeneuve V, Taussig D, Thomas F, et al. Evaluation of four candidate genes encoding proteins of the dopamine pathway in familial and sporadic Parkinson's disease: evidence for association of a DRD2 allele. Neurology 1997;48(6):1589-93.
78. Grevle L, Guzey C, Hadidi H, et al. Allelic association between the DRD2 TaqI A polymorphism and Parkinson's disease. Mov Disord 2000;15(6):1070-4.
79. Juyal RC, Das M, Punia S, et al. Genetic susceptibility to Parkinson's disease among South and North Indians: I. Role of polymorphisms in dopamine receptor and transporter genes and association of DRD4 120-bp duplication marker. Neurogenetics 2006;7(4):223-9.
80. Costa-Mallen P, Costa LG, Smith-Weller T, et al. Genetic polymorphism of dopamine D2 receptors in Parkinson's disease and interactions with cigarette smoking and MAOB intron 13 polymorphism. J Neurol Neurosurg Psychiatry 2000;69(4):535-7.
81. Pastor P, Munoz E, Obach V, et al. Dopamine receptor D2 intronic polymorphism in patients with Parkinson's disease. Neurosci Lett 1999;273(3):151-4.
82. Tan EK, Tan Y, Chai A, et al. Dopamine D2 receptor TaqIA and TaqIB polymorphisms in Parkinson's disease. Mov Disord 2003;18(5):593-5.
83. Wang J, Liu ZL, Chen B. Association study of dopamine D2, D3 receptor gene polymorphisms with motor fluctuations in PD. Neurology 2001;56(12):1757-9.
84. Woo NH, Teng HK, Siao CJ, et al. Activation of p75NTR by proBDNF facilitates hippocampal long-term depression. Nat Neurosci 2005;8(8):1069-77.
85. Graham DL, Edwards S, Bachtell RK, et al. Dynamic BDNF activity in nucleus accumbens with cocaine use increases selfadministration and relapse. Nat Neurosci 2007;10(8):1029-37.
86. Cheng CY, Hong CJ, Yu YW, et al. Brain-derived neurotrophic factor (Val66Met) genetic polymorphism is associated with substance abuse in males. Brain Res Mol Brain Res 2005; 140(1-2):86-90.
87. Uhl GR, Liu QR, Walther D, et al. Polysubstance abusevulnerability genes: genome scans for association, using 1,004 subjects and 1,494 single-nucleotide polymorphisms. Am J Hum Genet 2001;69(6):1290-300.
88. Flanagin BA, Cook EH Jr, de Wit H. An association study of the brain-derived neurotrophic factor Val66Met polymorphism and amphetamine response. Am J Med Genet B Neuropsychiatr Genet 2006;141B(6):576-83.
89. Beuten J, Payne TJ, Ma JZ, Li MD. Significant association of catechol-O-methyltransferase (COMT) haplotypes with nicotine dependence in male and female smokers of two ethnic populations. Neuropsychopharmacology 2006;31(3):675-84.
90. Lang UE, Sander T, Lohoff FW, et al. Association of the met66 allele of brain-derived neurotrophic factor (BDNF) with smoking. Psychopharmacology (Berl) 2007;190(4):433-9.
91. Matsushita S, Kimura M, Miyakawa T, et al. Association study of brain-derived neurotrophic factor gene polymorphism and alcoholism. Alcohol Clin Exp Res 2004;28(11): 1609-12.
92. Itoh K, Hashimoto K, Shimizu E, et al. Association study between brain-derived neurotrophic factor gene polymorphisms and methamphetamine abusers in Japan. Am J Med Genet B Neuropsychiatr Genet 2005;132B(1):70-3.
93. Fumagalli F, Racagni G, Riva MA. Shedding light into the role of BDNF in the pharmacotherapy of Parkinson's disease. Pharmacogenomics J 2006;6(2):95-104.
94. Mogi M, Togari A, Kondo T, et al. Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease. Neurosci Lett 1999;270(1):45-8.
95. Masaki T, Matsushita S, Arai H, et al. Association between a polymorphism of brain-derived neurotrophic factor gene and sporadic Parkinson's disease. Ann Neurol 2003;54(2):276-7.
96. Momose Y, MurataM, Kobayashi K, et al. Association studies of multiple candidate genes for Parkinson's disease using single nucleotide polymorphisms. Ann Neurol 2002;51(1):133-6.
97. Hong CJ, Liu HC, Liu TY, et al. Brain-derived neurotrophic factor (BDNF) Val66Met polymorphisms in Parkinson's disease and age of onset. Neurosci Lett 2003;353(1):75-7.
98. Hakansson A, Melke J, Westberg L, et al. Lack of association between the BDNF Val66Met polymorphism and Parkinson's disease in a Swedish population. Ann Neurol 2003;53(6):823.
99. Jentsch JD, Roth RH, Taylor JR. Role for dopamine in the behavioral functions of the prefrontal corticostriatal system: implications for mental disorders and psychotropic drug action. Prog Brain Res 2000;126: 433-53.
100. Kringelbach ML. The human orbitofrontal cortex: linking reward to hedonic experience. Nat Rev Neurosci 2005;6(9): 691-702.
101. Jentsch JD, Taylor JR. Impulsivity resulting from frontostriatal dysfunction in drug abuse: implications for the control of behavior by reward-related stimuli. Psychopharmacology (Berl) 1999;146(4):373-90.
102. Koob GF, Le Moal M. Neurobiological theories of addiction. In: Koob GF, Le Moal M, eds. Neurobiology of Addiction. London: Elsevier, 2006: 381-4.
103. RoeschMR, Calu DJ, Burke KA, Schoenbaum G. Should I stay or should I go? Transformation of time-discounted rewards in orbitofrontal cortex and associated brain circuits. Ann N Y Acad Sci 2007;1104: 21-34.
104. Ridley RM, Clark BA, Durnford LJ, Baker HF. Stimulusbound perseveration after frontal ablations in marmosets. Neuroscience 1993;52(3):595-604.
105. BrandM, Kalbe E, Labudda K, et al. Decision-making impairments in patients with pathological gambling. Psychiatry Res 2005;133(1):91-9.
106. Volkow ND, Fowler JS, Wolf AP, et al. Changes in brain glucose metabolism in cocaine dependence and withdrawal. Am J Psychiatry 1991;148(5):621-6.
107. Sekine Y, Minabe Y, Ouchi Y, et al. Association of dopamine transporter loss in the orbitofrontal and dorsolateral prefrontal cortices with methamphetamine-related psychiatric symptoms. Am J Psychiatry 2003;160(9):1699-701.
108. Reuter J, Raedler T, Rose M, et al. Pathological gambling is linked to reduced activation of the mesolimbic reward system. Nat Neurosci 2005;8(2):147-8.
109. Potenza MN, Steinberg MA, Skudlarski P, et al. Gambling urges in pathological gambling: a functional magnetic resonance imaging study. Arch Gen Psychiatry 2003;60(8):828-36.
110. Mimura M, Oeda R, Kawamura M. Impaired decisionmaking in Parkinson's disease. Parkinsonism Relat Disord 2006;12(3):169-75.
111. Perretta JG, Pari G, Beninger RJ. Effects of Parkinson disease on two putative nondeclarative learning tasks: probabilistic classification and gambling. Cogn Behav Neurol 2005;18(4):185-92.
112. Schott BH, Niehaus L, Wittmann BC, et al. Ageing and earlystage Parkinson's disease affect separable neural mechanisms of mesolimbic reward processing. Brain 2007;130(Pt 9): 2412-24.
113. Frank MJ, Seeberger LC, O'Reilly RC. By carrot or by stick: cognitive reinforcement learning in parkinsonism. Science 2004;306(5703):1940-3.
114. Swainson R, Rogers RD, Sahakian BJ, et al. Probabilistic learning and reversal deficits in patients with Parkinson's disease or frontal or temporal lobe lesions: possible adverse effects of dopaminergic medication. Neuropsychologia 2000;38(5):596-612.
115. Cools R, Barker RA, Sahakian BJ, Robbins TW. Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands. Cereb Cortex 2001;11(12):1136-43.
116. Robinson TE, Berridge KC. The psychology and neurobiology of addiction: an incentive-sensitization view. Addiction 2000;95(Suppl 2):S91-117.
117. Schultz W. Neural coding of basic reward terms of animal learning theory, game theory, microeconomics and behavioural ecology. Curr Opin Neurobiol 2004;14(2):139-47.
118. Schultz W, Dayan P, Montague PR. A neural substrate of prediction and reward. Science 1997;275(5306):1593-9.
119. Wyvell CL, Berridge KC. Intra-accumbens amphetamine increases the conditioned incentive salience of sucrose reward: enhancement of reward "wanting" without enhanced "liking" or response reinforcement. J Neurosci 2000;20(21):8122-30.
120. Robinson TE, Berridge KC. Addiction. Annu Rev Psychol 2003;54: 25-53.
121. Berke JD, Hyman SE. Addiction, dopamine, and the molecular mechanisms of memory. Neuron 2000;25(3):515-32.
122. Evans AH, Pavese N, Lawrence AD, et al. Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol 2006;59(5):852-8.
123. Robbins T, Mittleman G, O'Brien C, Winn P. The neuropsychological significance of stereotypy induced by stimulant drugs. In: Cooper S, Dourish C, eds. Neurobiology of Stereotyped Behaviour. Oxford: Clarendon Press, 1990: 25-63.
124. Silveira-Moriyama L, Evans AH, Katzenschlager R, Lees AJ. Punding and dyskinesias. Mov Disord 2006;21(12):2214-7.
125. Graybiel AM, Canales JJ, Capper-Loup C. Levodopa-induced dyskinesias and dopamine-dependent stereotypies: a new hypothesis. Trends Neurosci 2000;23(10 Suppl):S71-7.
126. Chen JF, Moratalla R, Impagnatiello F, et al. The role of the D(2) dopamine receptor (D(2)R) in A(2A) adenosine receptor (A(2A)R)-mediated behavioral and cellular responses as revealed by A(2A) and D(2) receptor knockoutmice. Proc Natl Acad Sci USA 2001;98(4):1970-5.
127. Tack E, De Cuypere G, Jannes C, Remouchamps A. Levodopa addiction. A case study. Acta Psychiatr Scand 1988;78(3):356-60.
128. Priebe S. Levodopa dependence: a case report. Pharmacopsychiatry 1984;17(4):109-10.
129. Kimber TE, Thompson PD, Kiley MA. Resolution of dopamine dysregulation syndrome following cessation of dopamine agonist therapy in Parkinson's disease. J Clin Neurosci 2008;15(2):205-8.
130. Kurlan R. Disabling repetitive behaviors in Parkinson's disease. Mov Disord 2004;19(4):433-7.
131. Miwa H, Morita S, Nakanishi I, Kondo T. Stereotyped behaviors or punding after quetiapine administration in Parkinson's disease. Parkinsonism Relat Disord 2004;10(3):177-80.
132. Dodd ML, Klos KJ, Bower JH, et al. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol 2005;62(9):1377-81.
133. O'Sullivan SS, Gallagher DA, Evans AH, et al. Dopamine dysregulation syndrome, impulse control disorders and subthalamic nucleus deep brain stimulation: a case series and literature review. Mov Disord 2007;22(S16, Suppl):S163.
134. Avanzi M, Baratti M, Cabrini S, et al. Prevalence of pathological gambling in patients with Parkinson's disease. Mov Disord 2006;21(12):2068-72.
135. Grosset KA, Macphee G, Pal G, et al. Problematic gambling on dopamine agonists: not such a rarity. Mov Disord 2006;21(12):2206-8.
136. Izenwasser S, French D. Tolerance and sensitization to the locomotor-activating effects of cocaine aremediated via independent mechanisms. Pharmacol Biochem Behav 2002;73(4): 877-82.
137. Blanchet PJ, Calon F, Martel JC, et al. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U- 91356A) in MPTP-exposed monkeys. J Pharmacol Exp Ther 1995;272(2):854-9.
138. Trujillo KA, Kubota KS, Warmoth KP. Continuous administration of opioids produces locomotor sensitization. Pharmacol Biochem Behav 2004;79(4):661-9.
139. Mamikonyan E, Siderowf AD, Duda JE, et al. Long-term follow-up of impulse control disorders in Parkinson's disease. Mov Disord 2008;23(1):75-80.
140. Koran LM, Bullock KD, Hartston HJ, et al. Citalopram treatment of compulsive shopping: an open-label study. J Clin Psychiatry 2002;63(8):704-8.
141. Courty E, Durif F, Zenut M, Courty P, Lavarenne J. Psychiatric and sexual disorders induced by apomorphine in Parkinson's disease. Clin Neuropharmacol 1997;20(2):140-7.
142. Weiss RD. Relapse to cocaine abuse after initiating desipramine treatment. JAMA 1988;260(17):2545-6.
143. Nomikos GG, Damsma G, Wenkstern D, Fibiger HC. Chronic desipramine enhances amphetamine-induced increases in interstitial concentrations of dopamine in the nucleus accumbens. Eur J Pharmacol 1991;195(1):63-73.
144. Pallesen S, Molde H, Arnestad HM, et al. Outcome of pharmacological treatments of pathological gambling: a review and meta-analysis. J Clin Psychopharmacol 2007;27(4):357-64.
145. Iancu I, Lowengrub K, Dembinsky Y, et al. Pathological gambling: an update on neuropathophysiology and pharmacotherapy. CNS Drugs 2008;22(2):123-38.
146. Zadikoff C, Munhoz RP, Asante AN, et al. Movement disorders in patients taking anticonvulsants. J Neurol Neurosurg Psychiatry 2007;78(2):147-51.
147. Brandt-Christensen M, Kvist K, Nilsson FM, et al. Treatment with antidepressants and lithium is associated with increased risk of treatment with antiparkinson drugs: a pharmacoepidemiological study. J Neurol Neurosurg Psychiatry 2006;77(6):781-3.
148. Sofuoglu M, Kosten TR. Novel approaches to the treatment of cocaine addiction. CNS Drugs 2005;19(1):13-25.
149. Metman LV, Del Dotto P, LePoole K, et al. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch Neurol 1999;56(11):1383-6.
150. Kashihara K, Imamura T. Amantadine may reverse punding in Parkinson's disease - observation in a patient. Mov Disord 2008;23(1):129-30.
151. Dutra L, Stathopoulou G, Basden SL, et al. A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry 2008;165(2):179-87.
152. Carroll KM, Onken LS. Behavioral therapies for drug abuse. Am J Psychiatry 2005;162(8):1452-60.
153. Stanton MD, Shadish WR. Outcome, attrition, and family-couples treatment for drug abuse: a meta-analysis and review of the controlled, comparative studies. Psychol Bull 1997;122(2):170-91.
154. Young KS. Cognitive behavior therapy with Internet addicts: treatment outcomes and implications. Cyberpsychol Behav 2007;10(5):671-9.
155. Oei TP, Gordon LM. Psychosocial factors related to gambling abstinence and relapse in members of gamblers anonymous. J Gambl Stud 2008;24(1):91-105.
156. Dowling N, Smith D, Thomas T. Treatment of female pathological gambling: the efficacy of a cognitive-behavioural approach. J Gambl Stud 2006;22(4):355-72.
157. Limousin P, Krack P, Pollak P, et al. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 1998;339(16):1105-11.
158. Houeto JL, Mesnage V, Mallet L, et al. Behavioural disorders, Parkinson's disease and subthalamic stimulation. J Neurol Neurosurg Psychiatry 2002;72(6):701-7.
159. Schupbach WM, Chastan N, Welter ML, et al. Stimulation of the subthalamic nucleus in Parkinson's disease: a 5 year follow up. J Neurol Neurosurg Psychiatry 2005;76(12):1640-4.
160. Bandini F, Primavera A, Pizzorno M, Cocito L. Using STN DBS and medication reduction as a strategy to treat pathological gambling in Parkinson's disease. Parkinsonism Relat Disord 2007;13(6):369-71.
161. Ardouin C, Voon V, Worbe Y, et al. Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. Mov Disord 2006;21(11):1941-6.
162. Smeding HM, Speelman JD, Koning-Haanstra M, et al. Neuropsychological effects of bilateral STN stimulation in Parkinson disease: a controlled study. Neurology 2006;66(12):1830-6.
163. Smeding H, Goudriaan A, Foncke E, et al. Pathological gambling after bilateral STN stimulation in Parkinson disease. J Neurol Neurosurg Psychiatry 2007;78(5) 517-9.
164. Morgan JC, diDonato CJ, Iyer SS, et al. Self-stimulatory behavior associated with deep brain stimulation in Parkinson's disease. Mov Disord 2006;21(2):283-5.
165. Lu C, Bharmal A, Suchowersky O. Gambling and Parkinson disease. Arch Neurol 2006;63(2):298.
166. Voon V, Potenza MN, Thomsen T. Medication-related impulse control and repetitive behaviors in Parkinson's disease. Curr Opin Neurol 2007;20(4):484-92.